Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Bohrane Slama"'
Autor:
Emmanuel Gyan, Pierre Fenaux, Pascale Cony-Makhoul, Odile Beyne-Rauzy, Kamel Laribi, Clémence Santana, Bohrane Slama, Jean-Thomas Giraud, Clément Gaudin, Laurence Sanhes, Ana Berceanu, Sophie Dimicoli, Amina Cherait, Berangere Gruson, Groupe Francophone des Myélodysplasies, Jose Miguel Torregrosa, Thibault Comont, Vincent Jachiet, Marie-Agnès Azerad, Mathieu Meunier, Thomas Cluzeau, Claire Guerveno, Pr Lionel Ades, Thierry Guillaume, Ahmad Al Jijakli, Lenaïg Le Clech, Jonathan Broner
Publikováno v:
British Journal of Haematology. 194:336-343
Despite a moderate prevalence in low-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), thrombocytopenia remains a risk of severe bleeding and therapeutic options are still limited. There are only a few studies with elt
Autor:
Salomon Manier, Jill Corre, Cyrille Hulin, Kamel Laribi, Carla Araujo, Gian-Matteo Pica, Cyrille Touzeau, Pascal Godmer, Bohrane Slama, Lionel Karlin, Frederique Orsini-Piocelle, Mamoun Dib, Margaret Macro, Laurence Sanhes, Aurore Perrot, Jean Yves Mary, Jerome Lambert, Herve Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon
Publikováno v:
Blood. 140:1369-1370
Autor:
Brigitte Pegourie, Frédérique Orsini-Piocelle, Charles Zarnitsky, Benoit Bareau, Jean-Gabriel Fuzibet, Eric Voog, Philippe Rodon, Sophie Auger-Quittet, Xavier Leleu, Olivier Decaux, Eileen M Boyle, Bohrane Slama, Lotfi Benboubker, Gilles Pernod, Philippe Rey, Bruno Royer, Lionel Karlin, Cecile Leyronnas, Karim Belhadj-Merzoug, Manuel Cliquennois, Mourad Tiab, J.-L. Bosson
Publikováno v:
American Journal of Hematology. 94:635-640
The risk of venous thromboembolism (VTE) is higher in myeloma patients receiving immunomodulatory compounds. A VTE prophylaxis using low-molecular-weight heparin or aspirin is therefore proposed. Apixaban is an oral direct anti-Xa. Several studies ha
Autor:
Patrick F. Fogarty, Youlia M. Kirova, Marie Bannier, Christophe Bonnet, Bohrane Slama, Hervé Tilly, Romain Bosc, Fabien Le Bras, Luc Mathieu Fornecker, Emmanuelle Nicolas-Virelizier, Lucie Oberic, Thua-Ha Dao, Corinne Haioun, Romain Ricci, Manon Croix, Luc Xerri, Emmanuel Bachy, Emmanuel Itti, Lionel Tortolano, Marc André, Camille Laurent, Jean Marc Schiano De Colella, Virginie Fataccioli, Alexandra Traverse-Glehen, Nadia Amara, Philippe Gaulard
Publikováno v:
Blood. 138:1387-1387
Background: Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a rare form of T-cell lymphoma arising adjacent to a breast implant, recently recognized as a provisional entity in the 2017 revised World Health Organization (WHO) lym
Autor:
Thomas Gastinne, Julien Lazarovici, Veronique Edeline, Alexandra Traverse-Glehen, Anne Corby, Lysiane Molina, Nawel Belmecheri, Krimo Bouabdallah, Sandy Amorim, Diane Damotte, David Sibon, Rene-Olivier Casasnovas, Vincent Ribrag, Emmanuelle Nicolas-Virelizier, Franck Morschhauser, Alina Berriolo-Riedinger, Thierry Vander Borght, Anne-Claire Gac, Bohrane Slama, Eric Durot, Stéphanie Guidez, Vincent Launay, Pierre Feugier, Kamel Laribi, Marc André
Publikováno v:
Blood. 138:232-232
Background In contrast to the high cure rates in young patients (pts) treated with anthracycline-based chemotherapy, classical Hodgkin lymphoma (cHL) prognosis is poor in elderly pts, and very few data exist for pts considered too frail to receive st
Autor:
Katharina Götze, Jesús María Hernández Rivas, Guillermo Sanz, Teresa Bernal, Uwe Platzbecker, Blanca Xicoy, Ali Arar, Sylvain Thepot, Bohrane Slama, Consuelo del Cañizo, Maria Luz Amigo, Pierre Fenaux, Stefan Wickenhauser, Aristoteles Giagounidis, Agnès Guerci-Bresler, Joan Bargay, Raquel de Paz, Jose Angel Hernandez-Rivas, Félix López Cadenas, Eva Lumbreras, Benet Nomdedeu, Beatriz Arrizabalaga, Rosa Coll, María Díez-Campelo, Joaquín Sánchez
Publikováno v:
Blood. 136:28-29
Background: Most IPSS low and int1 (lower) risk MDS patients with isolated del(5q) develop RBC TD or need treatment for symptomatic anemia early after diagnosis (median time to transfusion/treatment of 20 months, López Cadenas et al abstract 3180 AS
Autor:
Christian Thiede, Oliver Tiebel, Sophie Park, Anne Sophie Kubasch, Klaus H. Metzeler, Sophie Dimicoli-Salazar, Katharina Götze, Katja Sockel, Marie-Luise Huetter-Kroenke, Marie-Pierre Gourin, Anna Mies, Pierre Fenaux, Dorothea Schipp, Kamel Laribi, Fatiha Chermat, Bohrane Slama, Richard F. Schlenk, Rosa Sapena, Pascale Cony-Makhoul, Jose Miguel Torregrosa Diaz, Silke Gloaguen, Georgia Metzgeroth, Regina Herbst, Anna Jonasova, Uwe Platzbecker, Benoit de Renzis, Lionel Ades, Aristoteles Giagounidis, Katja Jersemann
Publikováno v:
Blood. 136:44-45
*UP, LA contributed equally Introduction A significant proportion of lower risk (LR)-MDS patients present with thrombocytopenia, being associated with shortened survival and higher risk of progression to acute myeloid leukemia (AML). Treatment option
Autor:
Valérie Ugo, Nadine Carbuccia, Anne Murati, José Adélaïde, François Delhommeau, Frédéric Courtier, Max Chaffanet, Norbert Vey, Arnaud Guille, Bohrane Slama, Damien Luque Paz, Jerome Rey, Séverine Garnier, Pierre Hirsch, Daniel Birnbaum
Publikováno v:
Genes, Chromosomes & Cancer
Genes, Chromosomes & Cancer, 2019, 59 (1), pp.30-39. ⟨10.1002/gcc.22789⟩
Genes, Chromosomes & Cancer, 2019, 59 (1), pp.30-39. ⟨10.1002/gcc.22789⟩
INTRODUCTION In BCR-ABL1-negative myeloproliferative neoplasms, myelofibrosis (MF) is either primary (PMF) or secondary (SMF) to polycythemia vera or essential thrombocythemia. MF is characterized by an increased risk of transformation to acute myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64870cc4389065b6acb518cf6a87bf9
https://hal.science/hal-03634203
https://hal.science/hal-03634203
Autor:
Fabien Le Bras, Camille Laurent, Romain Bosc, Lionel Tortelano, Tu Ha Dao, Emmanuel Itti, Caroline Malhaire, Jean Marc Schiano de Collela, Marie Bannier, Emmanuel Bachy, Bohrane Slama, Luc Matthieu Fornecker, Lucie Oberic, Alexandra Traverse-Glehen, Youlia Kirova, Reyal Fabien, Herve Tilly, Emmanuelle Nicolas-Virelizier, Luc Xerri, Philippe Gaulard, Corinne Haioun
Publikováno v:
Blood. 132:1641-1641
Background: BIA-ALCL has recently been recognized as a distinct entity among T cell lymphomas. In the French Lymphopath network which has registered almost 60 000 lymphomas since 2010, 50 cases of BIA-ALCL were identified so far. Little is known abou
Autor:
Claude Preudhomme, François Dreyfus, Michael A. Morgan, Aline Renneville, Norbert Vey, Bohrane Slama, Véronique Della Valle, Laurianne Scourzic, Stéphane de Botton, Virginie Chesnais, Groupe Francophone des Myélodysplasies, Frederik Damm, Thomas Prebet, Odile Beyne-Rauzy, Michaela Fontenay, Aspasia Stamatoullas-Bastard, Nadine Carbuccia, Agnès Guerci-Bresler, Nicholas C.P. Cross, Lucile Couronné, Olivier Kosmider, Daniel Birnbaum, Claire Hidalgo-Curtis, Aline Schmidt-Tanguy, Olivier Bernard, Véronique Gelsi-Boyer
Publikováno v:
Blood. 119:3211-3218
A cohort of MDS patients was examined for mutations affecting 4 splice genes (SF3B1, SRSF2, ZRSR2, and U2AF35) and evaluated in the context of clinical and molecular markers. Splice gene mutations were detected in 95 of 221 patients. These mutations